Sales of Eli Lilly and Co.’s newest drug were an afterthought during its Oct. 21 report on third-quarter earnings. The blood thinner Effient totaled up $22.6 million in sales—a mere 0.4 percent of ...

The FDA has "formally admitted" that excluding a critic of Eli Lilly's Effient/prasugrel blood-thinner from a panel earlier this year was wrong, according to a press release from Rep. Maurice Hinchey, ...

(3) Important Safety Information about Effient Antiplatelet medicines, including Effient, can increase a patient's risk of bleeding. If patients have unexplained or excessive bleeding while on Effient ...

The Food and Drug Administration has approved Effient, a blood thinner made by Daiichi Sankyo and Eli Lilly , after an 18-month delay. But Effient will carry stark "black box" warnings about the risk ...

I'd blogged a few times that I thought the FDA might have a problem with "Effient," Eli Lilly's proposed name for its bloodthinner, because it was too close to efficient and all the connotations that ...

PARSIPPANY, N.J. and INDIANAPOLIS, Oral antiplatelet therapy Effient® (prasugrel) has been added to the updated clinical practice guidelines as a Class I recommended treatment option for patients ...

Tree huggers (just a colloquialism, not a dig) will be glad to know that biopharmaceutical companies submit their Food and Drug Administration filings for drug approval electronically these days. Dr.

Although current guidelines strongly recommend that dual antiplatelet therapy be administered early in treating patients with non-ST-segment-elevation acute myocardial infarction (NSTEMI), it is ...

Eli Lilly’s blood-thinner Effient was linked to higher rates of cancer than Bristol-Myers Squibb Co.’s rival product Plavix, research published today found. Patients taking Effient had a 43 percent ...

FLORENCE, ITALY — A study comparing ticagrelor (Brilinta, AstraZeneca) and prasugrel (Effient, Lilly/Daiichi-Sanyo) in patients with ST-segment-elevation MI (STEMI) undergoing primary PCI has shown ...

Drugmaker Eli Lilly and Co. said Thursday it turned a fourth-quarter profit on higher-than-expected revenue, but a key new drug saw a sharp sales drop after its summer debut. The Indianapolis ...

PARSIPPANY, N.J. and INDIANAPOLIS, March 29, 2011 /PRNewswire/ -- Oral antiplatelet therapy Effient® (prasugrel) has been added to the updated clinical practice guidelines as a Class I recommended ...